Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2009 | 09-2009 | 06-2009 | 03-2009 | 12-2008 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 8,454,000 | 6,131,000 | 4,019,000 | 1,975,000 | 8,163,000 |
| Depreciation Amortization | N/A | 1,712,000 | 1,098,000 | 548,000 | N/A |
| Income taxes - deferred | N/A | 1,099,000 | 720,000 | 321,000 | N/A |
| Accounts receivable | -934,000 | N/A | N/A | N/A | -431,000 |
| Accounts payable and accrued liabilities | 512,000 | N/A | N/A | N/A | 246,000 |
| Other Working Capital | -935,000 | -1,727,000 | -1,800,000 | -1,206,000 | -2,569,000 |
| Other Operating Activity | 5,094,000 | 510,000 | 534,000 | 315,000 | 4,360,000 |
| Operating Cash Flow | $12,191,000 | $7,725,000 | $4,571,000 | $1,953,000 | $9,769,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -10,468,000 | -7,508,000 | -4,394,000 | -2,395,000 | 3,282,000 |
| PPE Investments | -1,839,000 | -1,157,000 | -779,000 | -311,000 | -2,048,000 |
| Net Acquisitions | -925,000 | -890,000 | -31,000 | N/A | -1,079,000 |
| Purchase Of Investment | -296,000 | N/A | N/A | N/A | -10,578,000 |
| Sale Of Investment | 124,000 | N/A | N/A | N/A | 99,000 |
| Purchase Sale Intangibles | -795,000 | -471,000 | -370,000 | -136,000 | -41,000 |
| Other Investing Activity | -815,000 | -471,000 | -370,000 | -136,000 | -43,000 |
| Investing Cash Flow | $-14,219,000 | $-10,026,000 | $-5,574,000 | $-2,842,000 | $-10,367,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -491,000 | 6,810,000 | 6,648,000 | 4,705,000 | -118,000 |
| Debt Issued | 7,052,000 | N/A | N/A | N/A | 1,481,000 |
| Debt Repayment | -22,000 | N/A | N/A | N/A | -68,000 |
| Common Stock Issued | 724,000 | N/A | N/A | N/A | 2,875,000 |
| Common Stock Repurchased | -461,000 | 80,000 | -196,000 | -240,000 | -3,348,000 |
| Dividend Paid | -3,993,000 | -3,940,000 | -3,945,000 | -4,013,000 | -3,395,000 |
| Financing Cash Flow | $2,809,000 | $2,950,000 | $2,507,000 | $452,000 | $-2,573,000 |
| Exchange Rate Effect | 75,000 | 86,000 | 48,000 | -26,000 | -46,000 |
| Beginning Cash Position | 2,038,000 | 2,038,000 | 2,038,000 | 2,038,000 | 5,360,000 |
| End Cash Position | 2,894,000 | 2,773,000 | 3,590,000 | 1,575,000 | 2,038,000 |
| Net Cash Flow | $856,000 | $735,000 | $1,552,000 | $-463,000 | $-3,322,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 12,191,000 | 7,725,000 | 4,571,000 | 1,953,000 | 9,769,000 |
| Capital Expenditure | -1,887,000 | -1,268,000 | -853,000 | -368,000 | -2,106,000 |
| Free Cash Flow | 10,304,000 | 6,457,000 | 3,718,000 | 1,585,000 | 7,663,000 |